Intelligent Bio Solutions Inc. · NASDAQ:INBS
Intelligent Bio Solutions — Investor Presentation (April 2024)
23 slides from Intelligent Bio Solutions's investor presentation, Apr 9, 2024
Slide 1: Pioneering Pain-free Solutions
& : INTELLIGENT 48S BIO SOLUTIONS Pioneering Pain-free Solutions NASDAQ: INBS | April 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute “forward-looking” statements as defined in Section 27A of the Securities Act of 1933, as amended (the "Securities Act’), Section 21€ of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities L
Slide 3: Company Overview
Company Overview S6OF Sixtomers F DA 510(k) submission planned @4, 2024 U SA Product launch planned H1, 2025 Company Name Exchange / Ticker Market Cap Average Daily Volume* Revenue through to 12.31.2023 Adjusted Proforma Cash Balance Intelligent Bio Solutions Inc. Nasdaq; INBS $10.9 million as of 04
Slide 4: We're a medical technology company delivering intelligent, rapid, non-invasive testing solutions
We're a medical technology company delivering intelligent, rapid, non-invasive testing solutions. We're on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and improve the quality of life.
Slide 5: Slide 5
Slide 6: Simpler Drug Testing
Simpler Drug Testing NASDAG: INBS. 6
Slide 7: How it Works
NASDAG: INBS. How it Works When we ingest something, our bodies metabolize it to produce secondary chemicals (metabolites) detectable in blood, urine, saliva, and sweat. The metabolites we produce are specific to the substances we have consumed. The Intelligent Fingerprinting Drug Screening System d
Slide 8: Reduce Risk
as Reduce Risk ‘Aim to identify current impairment rather than past use with a detection window of only 16 hours.
Slide 9: Intelligent Fingerprinting Platform vs Other Drug Testing Standards
Intelligent Fingerprinting Platform vs Other Drug Testing Standards Urine Saliva IFP Window of Detection 1- 4 days Up to 48 hours Up to 16 hours 7 ‘Onsite o lab (1 ~ 3 days after lab Onsite o lab (1 day after lab - Typical Time for Results reel) receipt) ‘Onsite or lab ‘Typical Time of Test* Hoan an
Slide 10: Market Opportunity
é : me} 8 ie) oO é 3 2 2 3 & 5 eS € 2 3 E = a w g Market Opportunity
Slide 11: Growing Drug Use Disorders
Growing Drug Use Disorders 2021 Snapshot 39.5 45% 36% million increase of people in drug people had a in drug use disorders treatment in the Americas drug use disorder. ‘over the last ten years. use opioids as their primary drug of use. Statistics: NODC World Drug Report 2023, reporting on 2021 mark
Slide 12: Growing Drug Consumption
Growing Drug Consumption 2021 Snapshot 219 60 million million cannabis users, representing opioid users, 4% of the global adult population and making it the most used drug in the world. representing 1.2% of the global adult population. Statistics: NODC World Drug Report 2023, reporting on 2021 marke
Slide 13: Drug and Alcohol Testing per Industry 2021
Drug and Alcohol Testing per Industry 2021 Percentage Of New And Current Employees! Other services, except public administration Accommodation and food services ll Arts, entertainment, and recreation Halthareadcalsci— Educationalservices Professional ndbusines evvi—s5 Francais information Transporta
Slide 14: Drug Use in the Workplace
Drug Use in the Workplace + More than 70% of those abusing illicit drugs in the US are employed.! + $193 billion is the estimated annual economic impact of illicit drug use in the US $120 billion in lost productivity, $61 billion in criminal justice and $11 billion in healthcare costs.’ + Drugs are
Slide 15: ne of: oi: Mc O2e2 qi a: wm sé
ne of: oi: Mc O2e2 1 qi a: wm sé
Slide 16: Stages: PK Study, Method Comparison, 510(k) Submission, USA Product Launch
STAGE ONE STAGE TWO STAGE THREE STAGE FOUR Pharmacokinetic Method 510(k) USA Product (PK) Study Comparison Submission Launch Compare four types of Planned Q4, 2024 Planned H1, 2025 Compare the amounts of soreening tests to 3 opiates in fingerprint sweat validated, traceable LC- vs. blood, oral fluid
Slide 17: Global footprint and growth
< a = G 2. x if & @ 3 o > ® [o4 Global footprint and growth
Slide 18: Product Footprint | 360+ customers
Product Footprint | 360+ customers Intelligent Fingerprinting Drug Screening System 9 9 99 %o9 9 9 9 q ‘ ee 99 9 9 99 9 9 9 @ curently Setiing @ Penned Launch cy 2024 9 9 @ Planned Launch cy 2025 NASDAG: INBS 18
Slide 19: Revenue Growth
Revenue Growth Commercialized Regions P2288 3 28
Slide 20: ESG
2 E 3 S O 8
Slide 21: Customer Testimonials
Customer Testimonials “By using fingerprint drug testing, | no longer have to take people off a project for half a day for screening - we can conduct the tests there and then.” Robinson Brothers “From our initial cost analysis, we see fingerprint-based drug screening as highly cost- effective [...]
Slide 22: Customer Testimonials
Customer Testimonials James Jones & Sons Ltd “On-site results for multiple drug groups in just ten minutes makes Intelligent Fingerprinting a very efficient and innovative solution for James Jones & Sons Ltd to adopt.” Auctus Management Group “The Intelligent Fingerprinting test has many benefits, i
Slide 23: Thank You
Thank You www.ibs.inc | info@ibs.inc
Intelligent Bio Solutions — Investor Presentation (April 2024) on 6ix